# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN
- Date: 2026-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: modern shifted

## What we are working on

- She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow down **S**
- She is worried that her kidneys could fail and wants to know plainly what the numbers mean **S**
- She wants a plan that works on the road: medicines, readings, food and tests **S**

## Your goals

- Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated. Target: 2026-08-17. Recorded outcome: 122/76 in the clinic; home average 123/77 on losartan 100 mg and amlodipine 5 mg. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. Target: 2026-08-17. Recorded outcome: 286 to 294 mg/g at baseline; 128 mg/g at six months, 56% lower. **S**
- Kidney function stable, without a fall in eGFR of more than 30% after starting treatment. Target: 2026-08-17. Recorded outcome: eGFR 54 to 55 at baseline; 50 to 51 on treatment, a dip of under 10%. **S**
- Sodium under 2 g a day using foods she likes, at home and on the road. Target: 2026-08-17. Recorded outcome: Salt-free seasoning at home and ordering strategies on the road; restaurant meals still the hardest part. **S**
- LDL cholesterol lower by at least 30%. Target: 2026-04-27. Recorded outcome: 174 to 98 mg/dL on atorvastatin 20 mg, 44% lower. **S**
- Care that fits her work: every check scheduled around her travel, by her choice. Target: 2026-08-17. Recorded outcome: Laboratory checks booked before trips are planned after two missed checks; video visits between trips. **S**

## What we agreed to do

- Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travel. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weeks. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxen. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort Equations. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settled. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at home. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Mood and stress: PHQ-9 at intake and yearly. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumn. Guideline: Adult Immunization Schedule by Age (2026) **S**
- Gastroenteritis: oral rehydration, ondansetron as needed, losartan and empagliflozin held until she has eaten and drunk normally for 24 hours, then restarted; a metabolic panel within a week. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- As the nephrologist advised: losartan 50 mg, increased to 100 mg at two weeks if potassium and creatinine allow; empagliflozin 10 mg daily; sick-day rules for both; potassium and creatinine two to four weeks after each start or increase, accepting a creatinine rise of up to 30%; urine albumin at about three months, then every six months; blood pressure goal below 130/80, lower toward a systolic of 120 if well tolerated, with amlodipine as the next medicine. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Atorvastatin 20 mg daily, chosen with her after reviewing her 10-year ASCVD risk of 7.9% with CKD as a risk enhancer; lipid panel and ALT at four to twelve weeks. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Amlodipine 5 mg added for home readings above goal on losartan 100 mg; every laboratory check booked on a home day before her trips are scheduled, by her office, after two missed checks. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**

## Follow-up

- 2026-02-09: Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks **S**
- 2026-02-23: Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultation **S**
- 2026-03-09: Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram **S**
- 2026-04-27: Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin **S**
- 2026-06-08: Periodic adult preventive visit **S**
- 2026-08-17: Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead **S**

This teaching document does not replace care from a qualified clinician.
